Research
Hormonal
Patients older than 67 years showed a significant increase in fracture risk with GLP-1RA use, particularly those aged 68 to 77 years (5.61% vs. 3.65%, OR 2.25, CI [1.62 to 3.13]) and 78 to 88 years (9.28% vs. 5.10%, OR 4.99, CI [2.68 to 9.26]).
Older patients may be at higher risk for fractures when prescribed GLP-1RAs and should be monitored accordingly.
StrongSupportsmedium confidence
Subanalyses based on body mass index (BMI) and age group demonstrated increased fracture risk in the GLP-1RA group in patients... older than 67 years, including those aged 68 to 77 years (5.61% vs. 3.65%, NNH = 51, OR 2.25, CI [1.62 to 3.13]) and 78 to 88 years (9.28% vs. 5.10%, NNH = 24, OR 4.99, CI [2.68 to 9.26]).
Why this rating
Based on a large retrospective case-control study design.
Source
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Fracture Risk in Overweight or Obese, Nondiabetic Patients
Evangelia Constantine et al. · Journal of the American Academy of Orthopaedic Surgeons · 2025
DOI 10.5435/jaaos-d-24-01505
cohort · n=606364Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1RA use was associated with increased fracture risk in nondiabetic patients who were overweight or obese (3.05% vs. 2.61%, OR 1.19, CI [1.09 to 1.31]).Strong
- In patients with a BMI ≥40, fracture risk was significantly increased with GLP-1RA use (3.15% vs. 1.91%, OR 1.26, CI [1.04 to 1.52]).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →